Welcome to our dedicated page for Whitehawk Therapeutics SEC filings (Ticker: WHWK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Whitehawk Therapeutics, Inc. (Nasdaq: WHWK) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Whitehawk is a clinical-stage oncology therapeutics company focused on antibody-drug conjugate (ADC) cancer treatments, and its filings offer insight into financial results, development plans and corporate activities related to this strategy.
Among the key documents available are current reports on Form 8-K, which Whitehawk has used to furnish press releases announcing quarterly financial results and recent highlights. These filings reference information such as research and development spending, progress toward Investigational New Drug (IND) submissions for ADC programs like HWK-007 and HWK-016, and updates on the company’s three-asset ADC portfolio targeting PTK7, MUC16 and SEZ6.
On this page, users can also locate Whitehawk’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain more detailed discussions of the company’s oncology pipeline, risk factors, and financial condition. For investors interested in governance and compensation matters, proxy materials and related filings can provide additional context on board and executive oversight of the ADC development strategy.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand major updates without having to parse every page. Real-time updates from the SEC’s EDGAR system ensure that new WHWK filings, including future 10-Ks, 10-Qs and 8-Ks, appear promptly. Users can also review insider transaction reports on Form 4, when available, to see reported trades by directors and officers.
Together, these resources give a structured view of how Whitehawk reports its financial performance, clinical progress and corporate decisions to regulators and the market.
Whitehawk Therapeutics is refocusing as a clinical-stage oncology company built around three next-generation antibody-drug conjugates licensed from WuXi Biologics. Lead candidates HWK-007 and HWK-016 have cleared U.S. INDs, with Phase 1 trials recruiting and data readouts expected in the first half of 2027. An IND for HWK-206 is planned for mid-2026.
The company exited its prior FYARRO Business, selling 100% of the FYARRO operating subsidiary to KAKEN for $102.4 million, and no longer commercializes FYARRO. FYARRO generated net product sales of $7.1 million in 2025 and $26.0 million in 2024. Management believes existing cash, cash equivalents and short-term investments can fund planned operations into 2028.
Whitehawk Therapeutics reported full-year 2025 results, highlighting a transition to a pure-play oncology ADC company with three clinical and near-clinical assets. Cash, cash equivalents and short-term investments were $145.7 million as of December 31, 2025, up from $47.2 million a year earlier, and are expected to fund operations into 2028.
Product revenue fell to zero in 2025 from $25.98 million in 2024 following the divestiture of the AADI subsidiary, while net loss narrowed to $20.6 million from $63.7 million, aided by an $87.3 million gain on that sale. The company is actively recruiting Phase 1 trials for PTK7-targeted ADC HWK-007 and MUC16-targeted ADC HWK-016, plans an IND for HWK-206 in mid-2026, and expects initial Phase 1 data for HWK-007 and HWK-016 in the first half of 2027.
Whitehawk Therapeutics CEO David James Lennon reported routine equity compensation activity. He exercised restricted stock units into 16,250 shares of Common Stock at a conversion price of $0.0000 per share on March 1, 2026. On March 2, 2026, 5,100 Common Stock shares were sold at $3.3096 per share in a broker-assisted sale to satisfy tax withholding obligations related to the RSU vesting, rather than a discretionary market sale. After these transactions, he directly holds 44,579 shares of Common Stock and 32,500 restricted stock units.
Whitehawk Therapeutics, Inc. Chief Financial Officer Scott M. Giacobello reported compensation-related stock activity. On March 1, 2026, he exercised restricted stock units, converting 6,750 RSUs into the same number of common shares at a stated price of $0.0000 per share. A related entry shows 13,500 RSUs remaining after this vesting. On March 2, 2026, he completed a broker-assisted sale of 2,594 common shares at an average price of $3.3096 per share to satisfy tax withholding obligations tied to the RSU vesting. Following these transactions, he directly held 28,100 common shares.
Whitehawk Therapeutics officer Bryan Ball reported routine equity compensation activity. On March 1, 2026, he exercised restricted stock units, acquiring 5,000 shares of Common Stock at a conversion price of $0.00 per share, increasing his direct holdings.
On March 2, 2026, Ball disposed of 1,834 shares of Common Stock at an average price of $3.3096 per share in a broker-assisted transaction used to satisfy tax withholding obligations tied to the RSU vesting. After these transactions, he directly held 206,019 shares of Common Stock and 10,000 Restricted Stock Units.
Whitehawk Therapeutics, Inc. reported new equity compensation grants to its Chief Medical Officer. On December 1, 2025, the officer received a stock option covering 650,000 shares of common stock at an exercise price of $2.26 per share, along with 55,309 restricted stock units (RSUs).
The option vests over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date of December 1, 2025, and the remaining shares vesting in equal monthly installments so that the option is fully vested four years after that date, subject to continued service. All 55,309 RSUs are scheduled to vest in full on the one-year anniversary of the same vesting commencement date, also conditioned on the officer continuing as a service provider.
Whitehawk Therapeutics reported Q3 2025 results marked by its transition to a preclinical ADC portfolio. The quarter showed $0 revenue and a net loss of $17.7 million, driven by $19.5 million in operating expenses and offset by $1.9 million in interest income. For the nine months, the company recorded net income of $2.7 million, primarily due to an $87.3 million gain on the FYARRO business sale.
Liquidity strengthened with cash, cash equivalents and short‑term investments of $162.6 million as of September 30, 2025. The company paid $38.0 million plus 6% VAT in April 2025 under its WuXi Biologics license covering three ADCs (MUC16, PTK7, SEZ6). The FYARRO divestiture closed for $102.4 million on March 25, 2025, and a March 2025 private placement added $94.4 million net. An ATM of up to $75.0 million remains unused. Shares outstanding were 47,128,362 as of November 4, 2025.
Whitehawk Therapeutics reported that it issued a press release announcing financial results for the quarter ended September 30, 2025. The release is included as Exhibit 99.1 and is incorporated by reference.
The company states the information under Item 2.02 and Item 9.01 (including Exhibit 99.1) is being furnished, not filed, and therefore is not subject to the liabilities of Section 18 of the Exchange Act, unless specifically incorporated by reference elsewhere.
Coastlands-related parties report beneficial ownership of 2,819,215 shares of Whitehawk Therapeutics common stock, representing 5.98% of the outstanding shares based on 47,128,362 shares cited as of August 4, 2025. The holdings are reported across Coastlands Capital LP, Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC and Matthew D. Perry. Voting and dispositive power is reported as shared for most entities, with Coastlands Capital GP LLC showing sole voting and dispositive power in one cover-sheet entry, while other reporting persons indicate shared power. The filing states the securities were acquired and are held in the ordinary course of business and are not intended to change or influence control of the issuer.
In its first quarter post-divestiture, Whitehawk Therapeutics (WHWK) filed a Q2 2025 10-Q showing a markedly stronger balance sheet and a shift to pre-clinical R&D.
Liquidity: Cash, cash equivalents and short-term investments rose to $177.2 M from $47.2 M at YE-24, funded by the $102.4 M sale of FYARRO (closed 25 Mar 25) and a $100 M PIPE (21.6 M shares & 20.1 M pre-funded warrants at $2.40).
Operations: With FYARRO gone, Q2 revenue fell to $0 (vs $6.2 M). R&D expense jumped to $48.8 M (Q2 24: $13.1 M) after paying the remaining $38 M WuXi license fee for three antibody-drug conjugate (ADC) programs. SG&A declined 25 % YoY to $5.9 M. Net loss widened to $52.6 M (-$0.76/sh).
Six-month view: An $87.4 M gain on the FYARRO sale produced $20.4 M net income for 1H 25, yet operating cash burn reached $64.8 M.
- Total assets: $180.8 M; liabilities: $8.8 M; no debt.
- Equity climbed to $172.1 M and shares outstanding to 47.1 M (8 Aug 25).
- Outstanding dilution: 22.1 M pre-funded warrants & 7.6 M options.
Outlook: Management believes current cash funds ≥12 months of accelerated ADC development; future value creation now hinges on advancing these pre-clinical candidates into the clinic.